首页> 外文期刊>国际肝胆胰疾病杂志(英文版) >AFPlevelandhistologicdifferentiationpredict thesurvivalofpatientswithlivertransplantation forhepatocellularcarcinoma
【24h】

AFPlevelandhistologicdifferentiationpredict thesurvivalofpatientswithlivertransplantation forhepatocellularcarcinoma

机译:AFP水平和组织学差异预测肝细胞癌肝移植患者的生存率

获取原文
获取原文并翻译 | 示例
       

摘要

BACKGROUND: In  liver  transplantation  or  resection  for hepatocellular carcinoma (HCC), patient selection depends on morphological features. In patients with HCC, we performed a clinicopathological analysis of risk factors that affected survival after liver transplantation. METHODS: In 389 liver transplantations performed from 2004 to 2010, 102 were for HCC patients. Data were collected retrospectively  from  the  Organ  Transplantation  Center Database. Variables were as follows: age, gender, preoperative alpha-fetoprotein (AFP) levels, Child-Pugh and MELD scores, prognostic  staging  criteria  (Milan  and  UCSF),  etiology, number of tumors, the largest tumor size, total tumor size, multifocality,  intrahepatic  portal  vein  tumor  thrombosis, bilobarity, and histological differentiation. RESULTS: One  hundred  and  two  patients  were  evaluated. The 5-year overall survival rate was 56.5%. According to the UCSF criteria, 63% of the patients were within and 37% were beyond UCSF (P=0.03). Ten patients were excluded (one with ifbrolamellary HCC and 9 because of early postoperative death without HCC recurrence), and 92 patients were assessed. The mean age of the patients was 56.5±6.9 years. Sixty-two patients underwent  living  donor  liver  transplantations.  The  mean follow-up time was 29.4±22.6 months. Fifteen patients (16.3%) died in the follow-up period due to HCC recurrence. Univariate analysis showed that AFP level, intrahepatic portal vein tumor thrombosis, histologic differentiation and UCSF criteria were signiifcant factors related to survival and tumor recurrence. The 5-year estimated overall survival rate was 62.2% in all patients. According to the UCSF criteria, and the 5-year overall survival rate was 66.7% within and 52.7% beyond the criteria (P=0.04). Multivariate analysis showed that AFP level and poor differentiation were independent factors. CONCLUSIONS: For  proper  patient  selection  in  liver  trans-plantation for HCC, prognostic criteria related to tumor biology (especially AFP level and histological differentiation) should be considered. Poor differentiation and higher AFP levels are indicators of poor prognosis after liver transplantation.
机译:背景:肝细胞癌(HCC)的“肝内移植”或“切除”取决于患者的形态学特征。在肝癌患者中,我们对肝移植后影响生存的危险因素进行了临床病理分析。 方法:从2004年到2010年,在389例肝癌患者中进行了102例肝移植。从“器官移植中心”的数据库中追溯性地收集数据。变量如下:年龄,性别,术前α-甲胎蛋白水平,Child-Pugh和MELD评分,预后分期标准(米兰和UCSF),病因,肿瘤数量,最大肿瘤数,最大肿瘤数,肝内门静脉肿瘤,血栓形成,胆道压力和组织学分化。 结果:评估了“一百”和“两名”患者。 5年总生存率是56.5%。根据UCSF的标准,超过UCSF的患者中有63%在患者中,只有37%的患者(P = 0.03)。排除了十名患者(其中一例因未行HCC复发而在术后早期死亡,并伴有纤维状HCC和9例),并对92例患者进行了评估。病人的平均年龄为56.5±6.9岁。 62名患者接受了活体供体肝移植。平均随访时间为29.4±22.6个月。随访期间有15例(16.3%)患者死于HCC。单因素分析显示,AFP水平,肝内门静脉肿瘤性血栓形成,组织学分化和UCSF标准是影响生存率和复发的重要因素。所有患者的5年总生存率估计为62.2%。根据UCSF标准,其5年总生存率在该标准的66.7%之内和52.7%(P = 0.04)。多元分析表明,AFP水平和差的分化是独立的因素。 结论:应考虑为肝癌的肝移植选择合适的患者,考虑与肿瘤生物学(尤其是AFP水平和组织学分化)有关的预后标准。肝移植后分化差和AFP水平升高是预后不良的指标。

著录项

  • 来源
    《国际肝胆胰疾病杂志(英文版)》 |2012年第003期|256-261|共6页
  • 作者单位

    0rgan Transplantation Center, Sisli Florence Nightingale Hospital, Istanbul, Turkey Yaprak 0, Akyildiz M, Dayangac M, Demirbas BT, Guler N, Dogusoy GB, Yuzer Y and Tokat Y;

    0rgan Transplantation Center, Sisli Florence Nightingale Hospital, Istanbul, Turkey Yaprak 0, Akyildiz M, Dayangac M, Demirbas BT, Guler N, Dogusoy GB, Yuzer Y and Tokat Y;

    0rgan Transplantation Center, Sisli Florence Nightingale Hospital, Istanbul, Turkey Yaprak 0, Akyildiz M, Dayangac M, Demirbas BT, Guler N, Dogusoy GB, Yuzer Y and Tokat Y;

    0rgan Transplantation Center, Sisli Florence Nightingale Hospital, Istanbul, Turkey Yaprak 0, Akyildiz M, Dayangac M, Demirbas BT, Guler N, Dogusoy GB, Yuzer Y and Tokat Y;

    0rgan Transplantation Center, Sisli Florence Nightingale Hospital, Istanbul, Turkey Yaprak 0, Akyildiz M, Dayangac M, Demirbas BT, Guler N, Dogusoy GB, Yuzer Y and Tokat Y;

    0rgan Transplantation Center, Sisli Florence Nightingale Hospital, Istanbul, Turkey Yaprak 0, Akyildiz M, Dayangac M, Demirbas BT, Guler N, Dogusoy GB, Yuzer Y and Tokat Y;

    0rgan Transplantation Center, Sisli Florence Nightingale Hospital, Istanbul, Turkey Yaprak 0, Akyildiz M, Dayangac M, Demirbas BT, Guler N, Dogusoy GB, Yuzer Y and Tokat Y;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

  • 入库时间 2022-08-19 03:39:18
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号